Start with the UK indication
Ozempic is licensed for adults with type 2 diabetes who have insufficient control. Wegovy holds weight-management authorisations, and the injection also carries cardiovascular and MASH indications in its current UK information. So the first question is which condition you are being treated for. One prescription does not meet the clinical or funding criteria for the other brand because the molecule is shared.
Wegovy comes as a tablet and an injection
Wegovy is no longer only an injection brand in the UK. A daily tablet gained UK approval in June 2026. A phrase such as "Wegovy dose" is now incomplete unless you say tablet or injection. The dose, the daily or weekly routine and the absorption all differ. Swallowing a tablet and injecting the same number of milligrams would not give the same effect.
Trial percentages do not transfer between brands
STEP 1 tested semaglutide injection at an obesity treatment dose in adults without diabetes. Ozempic's SUSTAIN programme answered diabetes questions. Dose and population shape how you read each result. Quoting a Wegovy obesity figure as a promised Ozempic outcome misleads, even though both contain semaglutide. Read the trial name and methods as well as the active ingredient in the headline.
Off-label prescribing needs a clear explanation
A clinician can sometimes prescribe outside a product's licence when there is a professional reason, but the licence itself stays the same. If you are offered Ozempic for weight management alone, ask why the prescriber chose this option, what evidence supports the choice and how follow-up will work. Accurate information describes the licence status plainly and does not present every semaglutide use as an authorised Ozempic indication.
Shared safety advice, different instructions
Semaglutide precautions cover stomach and bowel side effects, hydration and specific advice about eye safety. Diabetes and other glucose-lowering medicines also change what needs monitoring. Never use two semaglutide brands together, and never use a second brand as a top-up. Tell every prescribing service about injections and tablets you get elsewhere so nobody duplicates your treatment by accident.
Handling a proposed switch
Ask for the exact new product, form, dose and start date. If you have diabetes, confirm who will monitor your glucose, what to do if symptoms appear and what happens if supply fails. You do not need to guess from pen colours or online conversion charts. You want a clear treatment plan with a justified indication, written instructions and a named clinician responsible for your review.
Keep the indication in your medical record
When a semaglutide prescription changes, your record should state the reason for the medicine. A new clinician then knows how to read your glucose monitoring, weight-management reviews and other goals. If you have both diabetes and obesity, both may count. Your team still needs to know the product's authorisation and the local funding pathway. A brand swap made only to match stock causes confusion unless the prescriber reviews the dose, instructions and intended use. If entries contradict each other, ask the team to correct them. Do not pick one yourself.
Sources
Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.
- Ozempic: UK prescribing information medicines.org.uk
- Wegovy injection: UK prescribing information medicines.org.uk
- MHRA: UK approval of Wegovy tablets gov.uk
- STEP 1: original trial publication nejm.org
- MHRA: semaglutide and NAION gov.uk
Spotted something out of date? Report a mistake.